Oncotelic Therapeutics (OTCQB: OTLC) announced the launch of its artificial intelligence-powered good manufacturing practices (GMP) manufacturing services platform at the 2026 BIO International Convention in San Diego. The platform integrates the company's proprietary PDAOAI technology with advanced robotics from its collaboration with TechForce Robotics, aiming to support pharmaceutical, biotechnology, and advanced therapeutics companies in modernizing manufacturing operations through AI-driven workflows, digital quality systems, and intelligent automation.
According to the company, the platform is designed to handle electronic batch records, manufacturing documentation, GMP workflow digitization, quality and compliance functions, and process monitoring. Oncotelic also plans to showcase progress with its Deciparticle nanomedicine platform, including SAPU003, a clinical-stage intravenous everolimus program currently being evaluated in a Phase 1b study. The full press release is available at https://ibn.fm/upnBW.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. The company's pipeline includes late-stage therapeutic candidates, and it benefits from the extensive patent portfolio of its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued U.S. patents. Oncotelic also licenses and co-develops drug candidates through joint ventures, such as its 45% ownership of GMP Bio.
The PDAOAI platform is integral to Oncotelic's strategy for drug discovery, lab automation, and AI-assisted GMP manufacturing. Through its relationship with SAPU Bio, an OEB-5 sterile injectable cGMP manufacturing facility, PDAOAI underpins the new platform and the ongoing joint development with TechForce Robotics, Oncotelic's strategic robotics and automation partner. TechForce Robotics, the operating brand of Nightfood Holdings, Inc., designs and deploys purpose-built robotics and automation solutions for service, hospitality, and pharmaceutical manufacturing applications. More information about TechForce Robotics can be found at https://www.techforcerobotics.com.
This launch represents a significant step in integrating AI and robotics into pharmaceutical manufacturing, potentially streamlining compliance and production processes. The implications for the industry include reduced operational inefficiencies and enhanced quality control, as AI-driven systems can manage complex documentation and monitoring tasks. Oncotelic's focus on GMP digitization aligns with broader trends in pharmaceutical automation, where regulatory compliance and precision are critical. The collaboration with TechForce Robotics underscores a move toward collaborative innovation between biopharma and automation specialists.
For more information about Oncotelic Therapeutics, visit https://www.oncotelic.com. InvestorWire, which syndicated this press release, is a specialized communications platform for private and public companies, and is part of the Dynamic Brand Portfolio @IBN. Additional details about InvestorWire are available at https://www.InvestorWire.com.
